Lakefront Biotherapeutics(FRA) GXE

Market Cap€1.63B

Since IPON/A

5 YearN/A

1 YearN/A

1 MonthN/A

€24.30

-1.94%

-0.48Today

Lakefront Biotherapeutics Financials at a Glance

Market Cap

€1.63B

Revenue (TTM)

€990.57

Net Income (TTM)

€594.33

EPS (TTM)

€9.05

P/E Ratio

2.74

Dividend

€0.00

Beta (Volatility)

-0.03 (Low)

Dividend

€0.00

Beta (Volatility)

-0.03 (Low)

Price

€24.30

Volume

Open

€24.80

Price

€24.30

Volume

Open

€24.80

Previous Close

€24.30

Daily Range

€24.30 - €24.80

52-Week Range

€22.32 - €31.86

Estimated Earnings Date

N/A

Dividend

€0.00

Beta (Volatility)

-0.03 (Low)

Price

€24.30

Volume

Open

€24.80

Previous Close

€24.30

Daily Range

€24.30 - €24.80

52-Week Range

€22.32 - €31.86

Estimated Earnings Date

N/A

GXE News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Lakefront Biotherapeutics

Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. Its clinical pipeline includes filgotinib, GLP3667, Toledo program, and idiopathic pulmonary fibrosis. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.

Industry

Biotechnology

Sector

Health Care

Employees

196

CEO

Henry O. Gosebruch, CPA

Website

www.galapagos.com

GXE Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

20.12%

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

36.50%

Dividend Yield

0.00%

Payout Ratio

N/A

Stock Overview

Market Cap

€1.63B

Shares Outstanding

65.66M

Volume

Avg. Volume

10.515

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

Lakefront Biotherapeutics Performance Analysis

Lakefront Biotherapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	EUR 241,249,000	-50.2%
2023	2023-12-31	EUR 239,724,000	-0.6%
2024	2024-12-31	EUR 275,649,000	15.0%
2025	2025-12-31	EUR 1,112,248,000	303.5%

Lakefront Biotherapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	EUR -3.32	73.3%
2023	2023-12-31	EUR 3.21	N/A
2024	2024-12-31	EUR 1.12	-65.0%
2025	2025-12-31	EUR 4.87	333.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q2 2026YOY CHG

Revenue

€12.11

+0.2%

Gross Profit

€2.97

+0.0%

Gross Margin

24.48%

+0.3%

Market Cap

€1.63B

N/A

Market Cap/Employee

€8.69

N/A

Employees

196

N/A

Net Income

€1.94

-0.0%

EBITDA

N/A

Quarterly Fundamentals

Name

Q2 2026YOY CHG

Total Cash

€142.31

+39.6%

Total Debt

€6.36

+0.8%

Accounts Receivable

€23.70

+0.4%

Inventory

€8.54

+0.3%

Long Term Debt

€4.77

+0.8%

Short Term Debt

€1.59

+0.7%

Return on Assets

16.58%

-2.3%

Return on Invested Capital

43.01%

-0.1%

Free Cash Flow

€14.30

-0.2%

Operating Cash Flow

€14.33

-0.2%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

^GSPCS&P 500

^GSPCS&P 500$7,684.24-0.00%

^DJIDJI

^DJIDJI$53,254.61-0.01%

^IXICNASDAQ

^IXICNASDAQ$26,319.55-0.00%

BTCBitcoin

BTCBitcoin$78,890.00-0.00%

SPCXSPCX

SPCXSPCX$142.81+0.01%

AAPLAAPL

AAPLAAPL$315.25-0.01%

AMZNAMZN

AMZNAMZN$258.45-0.03%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

PCGPG&E

PCGPG&E$13.27-0.20%

NVDANvidia

NVDANvidia$220.78+0.01%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF$9.97+0.11%

CNHCNH Industrial

CNHCNH Industrial$11.83+0.01%

NUNu Holdings

NUNu Holdings$14.55+0.02%

BITOProShares Trust - ProShares Bitcoin ETF

BITOProShares Trust - ProShares Bitcoin ETF$10.63+0.02%

AALAmerican Airlines Group

AALAmerican Airlines Group$13.43-0.02%

Questions About GXE

What is the current price of Lakefront Biotherapeutics?

Lakefront Biotherapeutics is trading at €24.30 per share.

What is the 52-week range for Lakefront Biotherapeutics?

Over the past 52 weeks, Lakefront Biotherapeutics has traded between €22.32 and €31.86.

How much debt does Lakefront Biotherapeutics have?

As of the most recent reporting period, Lakefront Biotherapeutics reported total debt of €6.36M.

How much cash does Lakefront Biotherapeutics have on hand?

Lakefront Biotherapeutics reported €135.95M in cash and cash equivalents in its most recent financial results.

What is Lakefront Biotherapeutics’s dividend yield?

Lakefront Biotherapeutics does not currently have a dividend yield.

Lakefront Biotherapeutics(FRA) GXE

Lakefront Biotherapeutics Financials at a Glance

GXE News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Lakefront Biotherapeutics

GXE Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Lakefront Biotherapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About GXE

What is the current price of Lakefront Biotherapeutics?

What is the 52-week range for Lakefront Biotherapeutics?

How much debt does Lakefront Biotherapeutics have?

How much cash does Lakefront Biotherapeutics have on hand?

What is Lakefront Biotherapeutics’s dividend yield?

Premium Investing Services